{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/9a21c026\"></iframe>","width":"100%","height":180,"duration":653,"description":"Matthew Schultz, Ph.D., and Amy White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.(00:31) Would you share a little bit about yourself and your background? (01:11) Could you provide us with an overview of this particular peripheral neuropathy?  (03:09) Can you share the background as to how your team learned about this condition and how you considered testing for it? (04:42)Would you explain what you saw when you performed the urine test on the first patient? (05:26) Were you able to test additional patients with this condition? (06:09)Could you expand on why this urine test is important? (07:20) How does a health care provider order urine testing for SORD deficiency? (07:59) How does this new SORD urine test complement the existing Mayo Clinic Laboratories test menu? (08:55)Could you summarize the benefits of ordering this SORD urine test at Mayo?","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}